PF-05221304 is an Orally Active, Liver-Directed and Dual ACC1 (and ACC2) Inhibitor
The character of nonalcoholic fatty liver disease (NAFLD) is the accumulation of fat (in excess of 5%) within the hepatocytes. The molecular etiology of NASH is complex, including disordered metabolism,…